CXL-USA Warned for Improper Investigational New Drug Study

Drug Industry Daily
A A
The FDA issued Rockville, Md.-based CXL-USA a warning letter for failing to get agency approval before starting a clinical trial and for lax monitoring of the study.

To View This Article:

Login

Subscribe To Drug Industry Daily